News

A boy with atypical hemolytic uremic syndrome (aHUS) experienced a disease relapse followed by unusual symptoms, including bone tissue death and gallstones, after pausing treatment with Soliris (eculizumab). His case was described in the report, “Bilateral hip osteonecrosis and cholelithiasis after eculizumab discontinuation in atypical…

People with atypical hemolytic uremic syndrome (aHUS) have an immune cell profile distinct from that of healthy people and unaffected family members, a recent study reported. Its scientists identified a range of immune cell types, genes, and signaling pathways that could ultimately serve as disease biomarkers — with the…

Short-term use of Soliris (eculizumab) successfully treated atypical hemolytic uremic syndrome (aHUS) that had no genetic link in two young adults, one with a rare infection and the other with a rare autoimmune condition, according to a case report. Both men lacked variants in complement genes that can…

People with atypical hemolytic uremic syndrome (aHUS) who start treatment with Soliris (eculizumab) or Ultomiris (ravulizumab) — both marketed by Alexion — generally use fewer healthcare resources, according to a new U.S. study. Indeed, rates of insurance claims for aHUS patients starting on either therapy dropped substantially…

Reduced capillary density and capillary abnormalities were identified in people with atypical hemolytic uremic syndrome (aHUS) using a nailfold dermoscopy, a study in Turkey reports. Nailfold dermoscopy is a noninvasive technique that lets doctors evaluate the small blood vessels (capillaries) in the nail fold. These observations suggest the technique…

Plasma exchange combined with rituximab, an immunosuppressant, might prevent atypical hemolytic uremic syndrome (aHUS) from coming back after a kidney transplant, according to a small study from India. The study, “Kidney Transplant Outcomes in Patients with Atypical Hemolytic Uremic Syndrome,” was published in Transplantation Proceedings. aHUS is…

Treatment with the drug Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) initially failed to ease the symptoms of a middle-age woman with AHUS and multiorgan involvement, a case study reported. Higher Soliris doses eventually eased disease symptoms in all organs except the kidneys, which had to be replaced…

A synthetic psychoactive drug was identified as the trigger that led to the onset of atypical hemolytic uremic syndrome (aHUS) in a 37-year-old man who was genetically prone to develop the condition, a case study in Croatia reported. “Our case is the first report of aHUS with proven ……

Pregnancy was identified as the trigger event for atypical hemolytic uremic syndrome (aHUS) that resulted in kidney damage for a genetically predisposed woman in her mid-20s, a U.S. case study reported. The patient had a clinical history of poorly managed high blood pressure and often failed to comply with…

A 38-year-old man developed atypical hemolytic uremic syndrome (aHUS) and end-stage kidney disease (ESKD) after receiving his first dose of AstraZeneca’s COVID-19 vaccine, according to a case report. The patient was admitted to a hospital in Saudi Arabia one week after being vaccinated. Tests revealed changes in blood parameters…